President and CEO of TranS1 Ken Reali attributes the decrease to insurance denials for lumbar fusion surgery and ongoing AxiaLIF physician reimbursement pressures. However, Humana’s recent move to cover AxiaLIF and the possibility of other payors following suit could drive more positive results for the company in the future, Mr. Reali says.
Domestic revenues made up $5.2 million of total 4Q revenues, according to the news release.
Read the company news release about TranS1’s 4Q financial results.
Read other coverage about device company’s financial reports:
– Integra LifeSciences Reports $194.1M 4Q Revenue, 6% Increase
